Universal Poor Survival in Children With Medulloblastoma Harboring Somatic TP53 Mutations
- 10 March 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (8), 1345-1350
- https://doi.org/10.1200/jco.2009.23.5952
Abstract
Medulloblastoma is the prototype of treatment success in modern pediatric neuro-oncology. Unfortunately, 20% to 30% of tumors recur despite maximal resection and multimodal therapy. Multiple biologic prognostic markers have been investigated to predict recurrences, but controversy remains regarding their clinical utility. Because p53 immunopositivity is an adverse prognostic marker in pediatric medulloblastoma and TP53 mutations are associated with chemotherapy and radiation therapy resistance, we aimed to determine the extent and role of TP53 mutations in pediatric medulloblastoma treatment failure. One hundred eight of 111 consecutive patients diagnosed with medulloblastoma in our institution from 1995 to 2007 were included. Median follow-up time was 5.3 years in survivors. All samples were immunostained for p53 and erbB-2. Histologic grade and immunostaining were scored by two blinded reviewers. For 49 patients, frozen material was available for TP53 sequencing. The main outcome measures were overall and progression-free survival. Sixteen percent of sequenced medulloblastomas harbored a TP53 mutation. As a screening test, p53 immunohistochemistry was 100% sensitive and 83% specific for a TP53 mutation. Strikingly, all mutated tumors recurred early, and 5-year survival for average-risk patients was 0% for TP53-mutated medulloblastoma compared with 74% ± 8% for wild-type medulloblastoma (P < .0001). Furthermore, 75% of recurrences in average-risk patients were associated with TP53 mutations. On multivariate analysis, TP53 mutation status was the strongest adverse prognostic factor (hazard ratio = 10.4, P = .003). Lack of long-term survival in TP53-mutated medulloblastomas highlights the role of TP53 mutations in medulloblastoma resistance to conventional therapies and the need for alternative treatments, and prospective validation of these findings is needed.Keywords
This publication has 30 references indexed in Scilit:
- Management of and Prognosis With MedulloblastomaArchives of Neurology, 2008
- Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grailExpert Review of Anticancer Therapy, 2007
- Nodule Formation and Desmoplasia in Medulloblastomas—Defining the Nodular/Desmoplastic Variant and Its Biological BehaviorBrain Pathology, 2007
- Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trialThe Lancet Oncology, 2006
- Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJournal of Clinical Oncology, 2006
- β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour CommitteeJournal of Clinical Oncology, 2005
- Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young childrenThe Lancet Oncology, 2005
- Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy AloneNew England Journal of Medicine, 2005
- Morphophenotypic Variation Predicts Clinical Behavior in Childhood Non-Desmoplastic MedulloblastomasJournal of Neuropathology and Experimental Neurology, 2003
- TrkC Expression Predicts Good Clinical Outcome in Primitive Neuroectodermal Brain TumorsJournal of Clinical Oncology, 2000